Tags

Type your tag names separated by a space and hit enter

Idebenone for Leber's hereditary optic neuropathy.
Drugs Today (Barc) 2016; 52(3):173-81DT

Abstract

Idebenone is a rapidly absorbed, safe and well-tolerated drug and is currently the only clinically proven treatment option for Leber's hereditary optic neuropathy (LHON) patients. Idebenone (Raxone®) is approved by the European Medicines Agency for the treatment of LHON and has been available on the European market since 2015. Due to its molecular mode of action of bypassing the defective mitochondrial complex I, idebenone leads to improved energy supply and a functional recovery of retinal ganglion cells during the acute stage of the disease, thereby preventing further vision loss and promoting recovery of vision. Thus, commencing treatment shortly after the onset of symptoms is likely to have the best therapeutic effect, a hypothesis that is supported by the available clinical data.

Authors+Show Affiliations

Pharmacy, School of Medicine, University of Tasmania, Hobart, Australia. nguven@utas.edu.au.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27186591

Citation

Gueven, N. "Idebenone for Leber's Hereditary Optic Neuropathy." Drugs of Today (Barcelona, Spain : 1998), vol. 52, no. 3, 2016, pp. 173-81.
Gueven N. Idebenone for Leber's hereditary optic neuropathy. Drugs Today. 2016;52(3):173-81.
Gueven, N. (2016). Idebenone for Leber's hereditary optic neuropathy. Drugs of Today (Barcelona, Spain : 1998), 52(3), pp. 173-81. doi:10.1358/dot.2016.52.3.2463564.
Gueven N. Idebenone for Leber's Hereditary Optic Neuropathy. Drugs Today. 2016;52(3):173-81. PubMed PMID: 27186591.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Idebenone for Leber's hereditary optic neuropathy. A1 - Gueven,N, PY - 2016/5/18/entrez PY - 2016/5/18/pubmed PY - 2016/7/16/medline KW - Genetic disorders KW - Idebenone KW - Inherited mitochondrial respiratory chain diseases KW - LHON KW - Leber’s hereditary optic neuropathy KW - Metabolic diseases SP - 173 EP - 81 JF - Drugs of today (Barcelona, Spain : 1998) JO - Drugs Today VL - 52 IS - 3 N2 - Idebenone is a rapidly absorbed, safe and well-tolerated drug and is currently the only clinically proven treatment option for Leber's hereditary optic neuropathy (LHON) patients. Idebenone (Raxone®) is approved by the European Medicines Agency for the treatment of LHON and has been available on the European market since 2015. Due to its molecular mode of action of bypassing the defective mitochondrial complex I, idebenone leads to improved energy supply and a functional recovery of retinal ganglion cells during the acute stage of the disease, thereby preventing further vision loss and promoting recovery of vision. Thus, commencing treatment shortly after the onset of symptoms is likely to have the best therapeutic effect, a hypothesis that is supported by the available clinical data. SN - 1699-3993 UR - https://www.unboundmedicine.com/medline/citation/27186591/Idebenone_for_Leber's_hereditary_optic_neuropathy_ L2 - http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summaryn_pr?p_JournalId=4&p_RefId=2463564 DB - PRIME DP - Unbound Medicine ER -